Please assess the completion status of the following clinical trial:

Trial Title: Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Signed informed consent~* All cases of suspected MRSA bacteremia as determined by a patient with at least one blood culture growing gram-positive cocci in clusters with a clinical syndrome consistent with true bacteremia including fever, hypothermia (temperature \< 36.0º C), tachycardia (heart rate \> 100 beats/minute), hypotension (systolic blood pressure \< 90 mm Hg) or other clinical features of sepsis.~* All cases of right-sided native valve endocarditis due to MRSA~* Patients who are diagnosed with left-sided native valve endocarditis after randomization will be continued in the study~* Patients with MRSA bacteremia associated with infected foreign bodies, including vascular prostheses, orthopedic prostheses

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose vancomycin (Type: ACTIVE_COMPARATOR): Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
- High-dose daptomycin (Type: EXPERIMENTAL): Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)

Based on this trial design, predict the completion outcome and termination type (if applicable).